A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Palbociclib (Primary) ; Goserelin; Letrozole; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms PALTAN
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.
- 06 Jun 2017 Planned End Date changed from 31 Oct 2024 to 30 Nov 2024.
- 06 Jun 2017 Planned primary completion date changed from 31 Oct 2019 to 30 Nov 2019.